NCT06449040View on ClinicalTrials.gov

Treatment of Cutaneous Leishmaniasis With Liposomal Amphotericin B in the Elderly

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

March 1, 2019

Primary Completion Date

September 1, 2021

Study Completion Date

September 1, 2023

Conditions
Cutaneous Leishmaniasis, American
Interventions
DRUG

Liposomal amphotericin B (AmBisome®)

Liposomal amphotericin B (AmBisome®) - intravenous use, twice a week until total dose is achieved

Trial Locations (1)

40000

Corte de Pedra Health Post, Presidente Tancredo Neves

All Listed Sponsors
collaborator

Instituto Gonçalo Muniz FIOCRUZ BA

UNKNOWN

lead

Hospital Universitário Professor Edgard Santos

OTHER

NCT06449040 - Treatment of Cutaneous Leishmaniasis With Liposomal Amphotericin B in the Elderly | Biotech Hunter | Biotech Hunter